大冢和灵北精神分裂症药物Abilify Maintena获欧盟批准

2013-11-25 tomato 生物谷

大冢(Otsuka)和灵北(Lundbeck)11月21日宣布,长效版抗精神病药物Abilify Maintena(aripiprazole,阿立哌唑)上市许可申请(MAA)获欧盟委员会(EC)批准,作为每月一次的肌内注射(IM)剂型药物,用于口服阿立哌唑稳定病情的精神分裂症(schizophrenia)成人患者的维持治疗。 防止复发是治疗精神分裂症的关键。支持Abilify Mainten

大冢(Otsuka)和灵北(Lundbeck)11月21日宣布,长效版抗精神病药物Abilify Maintena(aripiprazole,阿立哌唑)上市许可申请(MAA)获欧盟委员会(EC)批准,作为每月一次的肌内注射(IM)剂型药物,用于口服阿立哌唑稳定病情的精神分裂症(schizophrenia)成人患者的维持治疗。

防止复发是治疗精神分裂症的关键。支持Abilify Maintena监管文件的关键性研究证明,在精神分裂症的长期治疗中,与安慰剂相比,Abilify Maintena能够降低复发的风险,同时疗效不逊色于口服阿立哌唑。

Abilify Maintena具有与口服阿立哌唑类似的耐受性,同时,与安慰剂相比,Abilify Maintena在患者个人和社会功能上表现出统计学意义的显著改善,在双盲治疗阶段结束时,高达93%的患者对Abilify Maintena治疗表现出及其满意、非常满意或有点满意。

在欧洲,Abilify Maintena是唯一一种每月一次的注射剂型的多巴胺D2部分激动剂,用于精神分裂症的维持治疗。

英文原文:Otsuka and Lundbeck's Once-Monthly
Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole

Preventing relapse is critical in the treatment of schizophrenia. Pivotal studies, that supported the EU submission, demonstrate that Abilify Maintena can reduce the risk of relapse relative to placebo and is non-inferior to oral aripiprazole in patients with schizophrenia*1,2
The approval of Abilify Maintena now provides patients with schizophrenia access to a once-monthly formulation with established efficacy together with a tolerability profile that is comparable to that of oral ABILIFY® (aripiprazole)*2
At the end of the randomized, double-blind treatment phase in one of the pivotal trials, 93 percent of patients reported being extremely, very or somewhat satisfied with Abilify Maintena treatment*3
Abilify Maintena is the only dopamine D2 partial agonist in a once-monthly, injectable form to receive marketing authorization in Europe for maintenance treatment of schizophrenia
Abilify Maintena will be the first commercialized product in Europe from the global alliance between Otsuka and Lundbeck which is focused on developing Central Nervous System (CNS) therapies worldwide
(Tokyo, Japan and Copenhagen, Denmark, Thursday, November 21, 213) – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced marketing authorization approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.

Abilify Maintena reduces the risk of relapse relative to placebo over the long-term and provides effective treatment of schizophrenia.*1,2 It has a tolerability profile similar to oral aripiprazole*1, and demonstrated statistically significant benefits on patients’ personal and social functioning as compared to placebo.*1,4 93 percent of patients treated with Abilify Maintena were extremely, very or somewhat satisfied with their treatment at the end of the double-blind treatment phase.*4

“We strongly believe the schizophrenia community will welcome the availability of Abilify Maintena to help improve outcomes for patients living with schizophrenia. As a company, our focus is to develop treatments to help protect against relapse and preserve brain function,” said Ole Vahlgren, CEO & President, Otsuka Europe. “We must partner with health care professionals and caregivers to help patients get the best treatments that focus on reducing the risk of relapse.”

“Studies have shown that the early use of long-acting injectables can prevent a person with schizophrenia from experiencing a relapse,”*5 said Ole Chrintz, SVP International Markets & Europe, Lundbeck. “Efficacy is important, but a treatment for a chronic condition such as schizophrenia also needs to be well tolerated so patients will stay on it over the long-term. We believe Abilify Maintena meets this need.”*1,2,3

About the Studies
The efficacy of Abilify Maintena was demonstrated in two double-blind, Phase III, randomized trials. The safety profile for Abilify Maintena was demonstrated to be similar to that of oral ABILIFY. The most frequently observed adverse drug reactions (ADRs) reported in ≥5 percent of patients in two double-blind controlled clinical trials of Abilify Maintena were weight increases (9.0 percent), akathisia (7.9 percent), insomnia (5.8 percent), and injection site pain (5.1 percent).*1,2

About Abilify Maintena
Abilify Maintena is the only dopamine D2 partial agonist in once-monthly, injectable form to receive marketing authorization for maintenance treatment in schizophrenia. Physicians now have an alternative treatment option, with a tolerability profile comparable to the well-established oral ABILIFY, to address the on-going need to reduce the risk of relapse in patients with schizophrenia.

The European label states that Abilify Maintena is a powder and solvent for prolonged-release suspension for intra-muscular (IM) injection. It is a once-monthly formulation of aripiprazole in a sterile lyophilized powder that is reconstituted with sterile water. Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.

After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.

About Schizophrenia and Disease Relapse
Schizophrenia is a disease characterized by a distortion in the process of thinking and of emotional responsiveness. It most commonly manifests as hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and is accompanied by significant social or occupational dysfunction. Onset of symptoms typically occurs in young adulthood, and the condition is chronic, often requiring lifelong treatment to mitigate symptoms.

Relapse of schizophrenia refers to an exacerbation or acute psychotic break that is characterised primarily by the emergence of positive symptoms such as hallucinations, delusions and disordered thinking.*6

Relapse can occur when a patient no longer responds to antipsychotic medication, does not take the medication as prescribed, or stops taking their medication altogether. There are many reasons patients stop taking their medication, including poor insight about their illness, side effects from current treatments, complicated medication regimen or lack of support from family.*7 Abilify Maintena is able to significantly reduce the risk of relapse in patients with schizophrenia.*1

It has been estimated that schizophrenia affects approximately one percent of the adult population in the U.S. and Europe, and approximately 24 million people worldwide.*8,9 In Europe there are approximately 4.4 million adults with schizophrenia,*10 prevalent equally in both genders.*11,12 While there is no cure for the disease, symptoms and risk of relapse can be managed in most patients with appropriate antipsychotic treatment. However, when the disease is not managed, patients are at increased risk of disease relapse, which can cause the re-emergence or worsening of psychotic symptoms.*13

Schizophrenia places a significant burden on society. It is regarded among the most financially costly illnesses and is according to the World Health Organization (WHO), the 8th leading cause of DALYs (lost healthy years) worldwide among patients between the age of 15-44.*11 With 50 percent of patients not receiving appropriate care and 80 percent of patients relapsing within the first 5 years,*14 there is a significant unmet need to be addressed in schizophrenia.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1403977, encodeId=ff3b14039e74c, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIXE1PadWxBeosSHpB06cC9uZflHWBnMib5rSPbq29kzxyzUPEqWfvlNl0DMmX9070Gdwbq4zwg4vg/132, createdBy=bfe92444551, createdName=bnurmamat, createdTime=Wed Nov 27 05:20:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589928, encodeId=6c35158992869, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Nov 27 05:20:00 CST 2013, time=2013-11-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1403977, encodeId=ff3b14039e74c, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIXE1PadWxBeosSHpB06cC9uZflHWBnMib5rSPbq29kzxyzUPEqWfvlNl0DMmX9070Gdwbq4zwg4vg/132, createdBy=bfe92444551, createdName=bnurmamat, createdTime=Wed Nov 27 05:20:00 CST 2013, time=2013-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589928, encodeId=6c35158992869, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Nov 27 05:20:00 CST 2013, time=2013-11-27, status=1, ipAttribution=)]

相关资讯

艾滋疫苗研究取得突破 新疫苗在兔子体内已见效

据此间媒体披露,南非金山大学(又译为“维特沃特斯兰德大学”)两名科学家在研究艾滋疫苗领域取得突破,他们研制的新疫苗在兔子体内已经见效,今后他们计划在猴子体内乃至人体进行试验。 这两名科学家是病毒学家玛莉亚·帕帕坦纳索普洛斯与病理学教授彭妮·摩尔,他们将于下周在金山大学做报告,介绍几项已经获得国际认可的研究成果。 在接受南非《泰晤士报》的采访时,帕帕坦纳索普洛斯指出,虽然通过避孕套和男性包皮

拜耳多吉美(Nexavar)新适应症用于分化型甲状腺癌获FDA批准

拜耳(Bayer)和Onyx制药11月22日宣布,口服多激酶抑制剂多吉美(Nexavar,通用名:sorafenib,索拉非尼)已获FDA批准,用于局部晚期或转移性放射性碘(RAI)难治性分化型甲状腺癌的治疗。 Nexavar是首个获FDA批准专门用于放射性碘(RAI)难治性分化型甲状腺癌的药物。 Nexavar新适应症的获批,是基于III期DECISION临床试验的数据,结果表明,与安慰

CHMP建议批准ViiV HIV新药Tivicay

葛兰素史克(GSK)和辉瑞(Pfizer)合资公司ViiV Healthcare 11月21日宣布,HIV新药Tivicay(dolutegravir,50mg片剂)上市许可申请(MAA)获得了欧洲药品管理局(EMA)人用医药产品委员会(CHMP)的积极意见。CHMP建议批准Tivicay联合其他抗逆转录病毒药物用于HIV成人感染者和12岁以上青少年感染者的治疗。 CHMP的积极意见,是基于

CHMP建议批准吉利德丙肝新药sofosbuvir

吉利德(Gilead)11月22日宣布,丙型肝炎药物Sovaldi(sofosbuvir 400mg 片剂)已获得了欧洲药品管理局(EMA)人用医药产品委员会(CHMP)的积极意见。CHMP建议批准Sovaldi联合其他药物,用于慢性丙型肝炎(HCV)成人感染者的治疗。 Sofosbuvir是一种每日一次的口服核苷类似物聚合酶抑制剂,开发用于慢性丙型肝炎病毒(HCV)感染的治疗。 在欧洲和

强生糖尿病新药INVOKANA获欧盟批准

强生(JNJ)旗下杨森(Janssen)宣布,糖尿病新药INVOKANA(canagliflozin)获欧盟委员会(EC)批准,用于2型糖尿病成人患者的治疗,以改善血糖控制。 今年9月,canagliflozin获得了欧洲药品管理局(EMA)人用医药产品委员会(CHMP)建议批准的积极建议。此外,canagliflozin已于今年3月获FDA批准,并于近期获得了澳大利亚的批准。 Canag

强生丙肝新药OLYSIO(simeprevir)获FDA批准

强生(JNJ)11月22日宣布,丙肝新药OLYSIO(simeprevir)已获FDA批准,联合聚乙二醇干扰素和利巴韦林(ribavirin),用于基因型1慢性丙型肝炎成人患者代偿性肝脏疾病(包括肝硬化)的治疗。 此前,FDA已于今年5月授予simeprevir新药申请(NDA)优先审查资格,同时该药于今年10月获得了FDA顾问委员会建议批准的积极意见。 Simeprevir监管文件的提交